skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pazopanib and anti-VEGF therapy

Review

(3144) Views  (1137) Full article downloads

Authors: Harry A Drabkin

Published Date March 2010 Volume 2010:2 Pages 35 - 40
DOI: http://dx.doi.org/10.2147/RRU.S5896

Harry A Drabkin

Medical University of South Carolina and Hollings Cancer Center, Charleston, SC, USA

Abstract: Pazopanib (VotrientTM, GlaxoSmithKline), a multi-kinase inhibitor with activity against VEGFR and other receptors, was recently approved by the FDA for the treatment of advanced renal cell carcinoma (RCC). Here, we review the history of its development, together with an overview of VEGF and its receptors and co-receptors. Results from selected clinical trial data in RCC and other malignant diseases are presented. Based on available evidence, pazopanib is an effective VEGFR inhibitor with demonstrable clinical activity in metastatic RCC and promising activity in other diseases. Like most kinase inhibitors, its activity is not restricted to VEGF receptors, which is reflected in its side-effect profile.

Keywords: pazopanib, VEGFR, renal cell carcinoma








Readers of this article also read:

The role of high-dose chemotherapy in the treatment of testicular cancer
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Editorial
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention
Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted
Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction